Dorsal Sural Nerve Conduction Study in the Assesment of Oxaliplatin Induced Peripheral Neuropathy Purposes: dorsal sural nerve (DSN) monitoring is a sensitive method for the detection of neuropathies. We performed a preliminary study to obtain evidence of its utility in the assessment of oxaliplatin-induced peripheral neuropathy. Patients: we evaluated 17 patients (5 women and 12 men, median age 60 years; range 42-76) affected by a gastrointestinal cancer, treated with an oxaliplatin-based regimen. Methods: patients were examined at the beginning of chemotherapy and after three months. At each time subjects underwent an antidromic conduction study of sural nerve (SN) and DSN. Results: before chemotherapy DSN Sensory Action Potential (SAP) median amplitude was 4,40 uV (range 1,9-9,9 uV) and median conduction velocity was 34,90 m/sec (27,2–43,5 m/sec); SN SAP median amplitude was 9,40 uV (5,4-25,7) and median conduction velocity was 50 m/sec (41-60,5); DSN SAP amplitude was pathological in three patients and SN SAP one in one patient. After three months of therapy DSN SAP median amplitude was 3,9 uV (1,5-6,6 uV) and median conduction velocity was 38,20 m/sec (29,9-42,6); SN SAP median amplitude was 9,30 uV (4,9-16,5) and median conduction velocity was 50,00 m/sec (40,4-62,1); DSN SAP amplitude was pathological in four and SN SAP in two patients. A decrease of 11,37% in DSN median SAP and of 1,06% in SN median SAP was seen after three months. Discussion: Oxaliplatin induced peripheral neuropathy determine a sensory distal neuronopathy in 20-30% of patients, associated to a decrease in SAP amplitude. In our series this decrease was detected more effectively in the DSN than in the SN even very early in the course of chemotherapy. Conclusion: the preliminary results obtained in this series suggest that DSN SAP might be used as an early marker of oxaliplatin-induced peripheral neurotoxicity. However, further indications could be obtained only prolonging the observation period and increasing the number of patients to be investigated prospectively.
Alberti, P., Frigeni, B., Cavaletti, G., Ferrarese, C., Ferrara, R., Piccirilli, C., et al. (2010). Dorsal sural nerve conduction study in the assessment of oxaliplatin induced peripheral neuropathy. Intervento presentato a: Congresso della Società Italiana di Neurologia - 23/27 Ottobre, Catania, Italia.
Dorsal sural nerve conduction study in the assessment of oxaliplatin induced peripheral neuropathy
ALBERTI, PAOLA
;CAVALETTI, GUIDO ANGELO;FERRARESE, CARLO;CORTINOVIS, DIEGO LUIGI;BIDOLI, PAOLOUltimo
2010
Abstract
Dorsal Sural Nerve Conduction Study in the Assesment of Oxaliplatin Induced Peripheral Neuropathy Purposes: dorsal sural nerve (DSN) monitoring is a sensitive method for the detection of neuropathies. We performed a preliminary study to obtain evidence of its utility in the assessment of oxaliplatin-induced peripheral neuropathy. Patients: we evaluated 17 patients (5 women and 12 men, median age 60 years; range 42-76) affected by a gastrointestinal cancer, treated with an oxaliplatin-based regimen. Methods: patients were examined at the beginning of chemotherapy and after three months. At each time subjects underwent an antidromic conduction study of sural nerve (SN) and DSN. Results: before chemotherapy DSN Sensory Action Potential (SAP) median amplitude was 4,40 uV (range 1,9-9,9 uV) and median conduction velocity was 34,90 m/sec (27,2–43,5 m/sec); SN SAP median amplitude was 9,40 uV (5,4-25,7) and median conduction velocity was 50 m/sec (41-60,5); DSN SAP amplitude was pathological in three patients and SN SAP one in one patient. After three months of therapy DSN SAP median amplitude was 3,9 uV (1,5-6,6 uV) and median conduction velocity was 38,20 m/sec (29,9-42,6); SN SAP median amplitude was 9,30 uV (4,9-16,5) and median conduction velocity was 50,00 m/sec (40,4-62,1); DSN SAP amplitude was pathological in four and SN SAP in two patients. A decrease of 11,37% in DSN median SAP and of 1,06% in SN median SAP was seen after three months. Discussion: Oxaliplatin induced peripheral neuropathy determine a sensory distal neuronopathy in 20-30% of patients, associated to a decrease in SAP amplitude. In our series this decrease was detected more effectively in the DSN than in the SN even very early in the course of chemotherapy. Conclusion: the preliminary results obtained in this series suggest that DSN SAP might be used as an early marker of oxaliplatin-induced peripheral neurotoxicity. However, further indications could be obtained only prolonging the observation period and increasing the number of patients to be investigated prospectively.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.